Related Experiment Video
Updated: Mar 31, 2026
07:52
Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts
Published on: April 26, 2018
9.5K
VEGF Manipulation in Glioblastoma
Oncology (Williston Park, N.Y.)
|October 17, 2015
Summary
Targeting angiogenesis, driven by vascular endothelial growth factor (VEGF), offers potential for glioblastoma treatment. Combining antiangiogenic therapies with other modalities may improve outcomes for high-grade gliomas.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Medical Research
Background:
- Glioblastoma is a fatal primary brain tumor.
- Current treatments (surgery, radiation, chemotherapy) have limited efficacy.
- Targeting angiogenesis, crucial for tumor growth, is a key therapeutic strategy.
Purpose of the Study:
- To review antiangiogenic therapies targeting vascular endothelial growth factor (VEGF) in glioblastoma.
- To discuss the evolution of these therapies and challenges in clinical application.
- To explore future directions for enhancing glioblastoma treatment.
Main Methods:
- Review of clinical trials and research on antiangiogenic agents.
- Analysis of strategies targeting VEGF and its receptors (VEGFR).
- Exploration of resistance mechanisms and combination therapies.
Main Results:
- Multiple antiangiogenic strategies (VEGF blockade, VEGF Trap, TKIs) have been investigated.
- Clinical trials have advanced understanding but yielded limited durable responses.
- Understanding of resistance mechanisms is crucial for optimizing therapy.
Conclusions:
- Antiangiogenic therapy for glioblastoma shows promise but requires further refinement.
- Combination therapies integrating antiangiogenic agents with radiation, chemotherapy, or immunotherapy may improve outcomes.
- Continued research into resistance mechanisms and novel combinations is essential for advancing glioblastoma treatment.
